University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans.

from News-Medical.Net Weight Loss News Feed http://ift.tt/1o1vCWn
Follow Us on Twitter
Follow Us on FB
Follow Us on Pinterest
Follow Us on G+
Follow Us on Instagram
Follow Us on Instagram
Follow Us on Delicious
Follow Us on Wordpress